Bharat Biotech restarts homegrown Covid jab exports
Airport staff unload carton boxes of India-made vaccine at Mumbai airport as part of the COVAX scheme. (Photo by INDRANIL MUKHERJEE/AFP via Getty Images)
INDIAN vaccine manufacturer Bharat Biotech on Monday (29) said it has resumed exporting Covaxin, its Covid-19 vaccine, and has executed orders in November that have been long pending.
According to a statement the Hyderabad-based company made on Twitter, its exports to additional nations will begin from December.
However, it was not immediately clear whether the exports were made under COVAX, the global vaccine-sharing facility.
ALSO READ: India’s Covaxin jab less effective than thought: study
Covaxin, which is said to be 78 per cent effective against severe cases of Covid, was approved for emergency-use listing by the World Health Organisation earlier in November.
Dengue outbreak makes India hospitals repurpose Covid beds
Covaxin is the only homegrown jab which is being used in India’s vaccination drive, even though it accounts for only about 11 per cent of the nearly 1.23 billion doses that the country has administered so far.
India resumed exporting Covid-19 vaccines to COVAX for the first time since April. The Serum Institute of India, the world’s biggest vaccine-manufacturer, said it was able to restart exports since it beat its target of making a billion doses of the AstraZeneca vaccine ahead of time.
India stopped the exports earlier this year after a devastating second wave of the coronavirus pandemic wreaked havoc, killing several thousands, to meet the domestic demand.